trending Market Intelligence /marketintelligence/en/news-insights/trending/mxopqtu8ietb9zj9cgqtaq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

ANI Pharmaceuticals launches authorized generic of bipolar drug

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


ANI Pharmaceuticals launches authorized generic of bipolar drug

ANI Pharmaceuticals Inc. launched an authorized generic of its bipolar drug Lithobid.

The lithium carbonate tablets will be available in 300 mg doses and will compete with existing generics in the market. IMS Health estimates that the U.S. market for lithium carbonate is about $19 million.